More than 50% of HIV diagnoses now occur in 48 counties in the United States. Cuyahoga County, home to Cleveland, is one of ...
LoveBScott on MSN
MISTR & SISTR Launch First-Ever National PrEP Day: A Bold Move to End HIV in the U.S.
Oct. 10, 2025, is officially the first-ever National PrEP Day, and MISTR and SISTR are going big. Their goal? Get 10,000 new people on PrEP in just 10 days. It’s ambitious, it’s impactful, and it just ...
Lukas Gage is opening up about how being cheated on changed the way he approaches his sexual health. The “White Lotus” star got candid in a sit-down with The Post about the time a partner gave him not ...
Scotland is making “good progress” towards the goal of eliminating transmission of the HIV virus by 2030, a new report has ...
AllAfrica on MSN
Two Drugmakers Will Sell The 6-monthly Anti-HIV Jab for The Price of The Daily HIV Prevention Pill
Hetero and Dr Reddy’s — will be funded by the Gates Foundation and Unitaid, respectively, to produce and sell the twice-a-year anti-HIV shot, lenacapavir, for $40 (around R692) per person per ...
In his first term, President Trump pledged to boost HIV spending, with the lofty goal of bringing the epidemic to heel by ...
Lots of scholarship assumes that partners in higher-quality relationships work together to reduce health-related risks. A new study tested this assumption.
A new survey launched by Global Black Gay Men Connect is seeking responses from Black gay men and Black trans community ...
Gilead drug deal opens door for $40-a-year generic version of groundbreaking HIV prevention overseas
Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...
Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...
Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...
A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results